A+T 丰富交互结构域蛋白 3a(Arid3a)损害胆汁淤积中 Mertk 介导的胞葬作用
本研究探讨 Arid3a 在胆汁淤积中调节巨噬细胞功能的作用,通过髓系特异性 Arid3a 敲除小鼠和三种胆汁淤积模型发现,Arid3a 缺失减轻胆汁淤积性肝损伤,机制上 Arid3a 直接结合 Mertk 启动子负调控其转录,从而损害巨噬细胞对凋亡胆管细胞的胞葬作用,Arid3a-Mertk 轴是胆汁淤积性肝病的潜在治疗靶点。
要点
- 髓系特异性 Arid3a 缺失减轻胆汁淤积性肝损伤,伴巨噬细胞积累减少。
- Arid3a 缺失巨噬细胞经 Mertk 上调增强对凋亡胆管细胞的胞葬作用。
- Arid3a 直接结合 Mertk 启动子负调控其转录,Arid3a-Mertk 轴为潜在靶点。
核心结论
- Arid3a 通过损害巨噬细胞对凋亡胆管细胞的 Mertk 介导胞葬作用促进胆汁淤积性肝损伤。
- Arid3a-Mertk 轴是胆汁淤积性肝病有前景的新治疗靶点。
- Arid3a 对慢性肝病的调控作用仍需进一步阐明。
研究设计与样本
- 研究采用髓系特异性 Arid3a 敲除小鼠,建立三种胆汁淤积小鼠模型,并通过 q-PCR、免疫组化、免疫荧光染色和流式细胞术评估基因和蛋白表达及细胞定位。
- 通过 RNA-seq 分析转录组,使用 Mertk 受体特异性抑制剂 UNC2025 进行体外和体内实验,并通过染色质免疫沉淀测序针对 Arid3a 和荧光素酶报告基因实验测定启动子活性。
主要发现
- 在胆汁淤积小鼠模型中,髓系特异性 Arid3a 缺失减轻胆汁淤积性肝损伤,伴随巨噬细胞积累减少。
- Arid3a 缺陷巨噬细胞表现出更修复的表型,该表型被 Mertk 特异性抑制剂 UNC2025 体外处理消除。
- Arid3a 缺陷巨噬细胞通过上调 Mertk 增强对凋亡胆管细胞的胞葬作用,Arid3a 通过直接结合 Mertk 启动子负调控其转录。
- 体内靶向 Mertk 有效逆转了 Arid3a 缺陷巨噬细胞的保护表型。
- 在原发性胆汁性胆管炎(PBC)和原发性硬化性胆管炎(PSC)中,Arid3a 在肝脏巨噬细胞和循环单核细胞中上调,Mertk 相应上调并与 Arid3a 表达负相关。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文指出 Arid3a 对慢性肝病的调控作用仍需进一步阐明。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Macrophages are key elements in the pathogenesis of cholestatic liver diseases. Arid3a plays a prominent role in the biologic properties of hematopoietic stem cells, B lymphocytes and tumor cells, but its ability to modulate macrophage function during cholestasis remains unknown. METHODS: Gene and protein expression and cellular localization were assessed by q-PCR, immunohistochemistry, immunofluorescence staining and flow cytometry. We generated myeloid-specific Arid3a knockout mice and established three cholestatic murine models. The transcriptome was analyzed by RNA-seq. A specific inhibitor of the Mertk receptor was used in vitro and in vivo. Promoter activity was determined by chromatin immunoprecipitation-seq against Arid3a and a luciferase reporter assay. RESULTS: In cholestatic murine models, myeloid-specific deletion of Arid3a alleviated cholestatic liver injury (accompanied by decreased accumulation of macrophages). Arid3a-deficient macrophages manifested a more reparative phenotype, which was eliminated by in vitro treatment with UNC2025, a specific inhibitor of the efferocytosis receptor Mertk. Efferocytosis of apoptotic cholangiocytes was enhanced in Arid3a-deficient macrophages via upregulation of Mertk. Arid3a negatively regulated Mertk transcription by directly binding to its promoter. Targeting Mertk in vivo effectively reversed the protective phenotype of Arid3a deficiency in macrophages. Arid3a was upregulated in hepatic macrophages and circulating monocytes in primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC). Mertk was correspondingly upregulated and negatively correlated with Arid3a expression in PBC and PSC. Mertk+ cells were located in close proximity to cholangiocytes, while Arid3a+ cells were scattered among immune cells with greater spatial distances to hyperplastic cholangiocytes in PBC and PSC. CONCLUSIONS: Arid3a promotes cholestatic liver injury by impairing Mertk-mediated efferocytosis of apoptotic cholangiocytes by macrophages during cholestasis. The Arid3a-Mertk axis is a promising novel therapeutic target for cholestatic liver diseases. IMPACT AND IMPLICATIONS: Macrophages play an important role in the pathogenesis of cholestatic liver diseases. This study reveals that macrophages with Arid3a upregulation manifest a pro-inflammatory phenotype and promote cholestatic liver injury by impairing Mertk-mediated efferocytosis of apoptotic cholangiocytes during cholestasis. Although we now offer a new paradigm to explain how efferocytosis is regulated in a myeloid cell autonomous manner, the regulatory effects of Arid3a on chronic liver diseases remain to be further elucidated.
引用
- Chen R, Huang B, Lian M, et al. A+T rich interaction domain protein 3a (Arid3a) impairs Mertk-mediated efferocytosis in cholestasis. J Hepatol. 2023. PMID: 37659731. doi:10.1016/j.jhep.2023.08.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。